Status: Closed
Activation Date: 2010MAY25
Closing Date: 2013AUG02
Phase: II
Description: A Phase II Study of Foretinib in Patients with Estrogen Receptor (ER), Progesterone Receptor (PR), and Human Epidermal Growth Factor Receptor 2 (HER2) Negative, Recurrent/Metastatic Breast Cancer.
Eligibility: Advanced or recurrent/metastatic invasive breast cancer, that is ER, PR and HER2 negative.
Objective: To determine the anti-tumour activity and toxicity of foretinib in this patient population.
Participation: Limited to invited centres
Lay Description:
Primary Publication Show
Other Publications Show
Inventory
Hide Tissue Samples
| Disease Site | Trial Code | Patients Accrued | Patients - Blocks | Patients - Slides | Patients - Blocks and/or Slides |
| IND | I197 | 47 | 41 | 44 | 44 |
(Core size is 0.6 mm)
Hide
Fluid Samples| Disease Site | Trial Code | Patients Accrued | TMA Blocks | Patients on TMA Blocks |
| IND | I197 | 47 | 2 | 18 |
| Disease Site | Trial Code | Patients Accrued | Patients - Whole Blood | Patients - Cellular Component of Blood | Patients - DNA extracted from Blood | Patients - RNA extracted from Blood | Patients - Plasma | Patients - Serum | Patients - Urine | Patients - Buccal |
| IND | I197 | 47 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |